CTOs on the Move

GN Resound

www.gnresound.com

 
GN ReSound is the undisputed technology leader in the global hearing instrument market and is one of several divisions of GN Great Nordic. To learn more about our parent company, Great Nordic, please click on the link below.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.gnresound.com
  • 8001 E Bloomington Fwy
    Minneapolis, MN USA 55420
  • Phone: 952.769.8000

Executives

Name Title Contact Details

Similar Companies

Data Circle Inc

Data Circle Inc is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zotec Partners

Zotec Partners is an industry leading provider of specialized medical billing and practice management services for the hospital-based specialty market. The company is committed to the continual pursuit of excellence in the physician revenue cycle management industry by delivering effective solutions through personalized service and measurable client results. Zotec Partners` proprietary processes and technology manage in excess of 70 million medical encounters across all 50 states.

Vitamin Angels

Vitamin Angels is a non-profit organization that distributes lifesaving and life-changing vitamins and minerals to children and mothers in need, working to improve maternal and child nutrition worldwide.

Telligen

Telligen is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in West Des Moines, IA. To find more information about Telligen, please visit www.telligen.org

Glytec System

Glytec is the insulin management software company for healthcare providers focused on improving the quality and cost of care. Its FDA-cleared titration software and proprietary algorithms power the only solution capable of delivering personalized diabetes treatment recommendations across the continuum of care, from hospital to home. With ongoing support from its team of doctors, nurses and technologists headquartered outside of Boston, Glytec improves outcomes and controls costs for the large population of patients requiring insulin treatment – including those with and without a diagnosis of diabetes.